CalliSpheres® drug-eluting beads (DEB) transarterial chemoembolization (TACE) is equally efficient and safe in liver cancer patients with different times of previous conventional TACE treatments: a result from CTILC study

• X. Zhang ^[1] ; J. Zhou ^[9] ; D.-D. Zhu ^[2] ; J. Huang ^[10] ; J.-H. Sun ^[1] ; T.-F. Li ^[11] ; C.-S. Shi ^[12] ; Z.-C. Sun ^[13] ; Q.-M. Hou ^[14] ; Z.-Y. Peng ^[1] ; W.-Q. Yu ^[3] ; J.-S. Ji ^[4] ; W.-J. Gu ^[15] ; G.-H. Zhou ^[1] ; X.-X. Xie ^[16] ; X.-H. Guo ^[5] ; G.-H. Cao ^[17] ; Z.-H. Yu ^[18] ; H.-H. Xu ^[19] ; J. Fang ^[20] ; S.-H. Ying ^[1] ; W.-H. Hu ^[21] ; W.-B. Ji ^[22] ; J. Han ^[23] ; X. Wu ^[6] ; J.-P. Zheng ^[7] ; J. Luo ^[7] ; Y.-T. Chen ^[7] ; T.-Y. Hu ^[3] ; L. Li ^[2] ; H.-J. Hu ^[6] ; H.-J. Du ^[8] ; Guoliang Shao ^[7]
  1. [1] Zhejiang University

     Zhejiang University

     China

     
  2. [2] Ningbo No. 2 Hospital

     Ningbo No. 2 Hospital

     China

     
  3. [3] Zhejiang Provincial People's Hospital

     Zhejiang Provincial People's Hospital

     China

     
  4. [4] Lishui Central Hospital

     Lishui Central Hospital

     China

     
  5. [5] Dalian Municipal Central Hospital

     Dalian Municipal Central Hospital

     China

     
  6. [6] Sir Run Run Shaw Hospital

     Sir Run Run Shaw Hospital

     China

     
  7. [7] Zhejiang Cancer Hospital

     Zhejiang Cancer Hospital

     China

     
  8. [8] Dongyang People's Hospital

     Dongyang People's Hospital

     China

     
  9. [9] Hangzhou Cancer Hospital, China
  10. [10] Ningbo Medical Center Lihuili Easter Hospital, China
  11. [11] Beilun District People’s Hospital of Ningbo, China
  12. [12] The Third Affiliated Hospital of Wenzhou Medical University, China
  13. [13] The First Affiliated Hospital of Zhejiang Chinese Medical University, China
  14. [14] Xixi Hospital of Hangzhou, China
  15. [15] Jiaxing Second Hospital, China
  16. [16] Xinchang People’s Hospital, China
  17. [17] Shulan (Hangzhou) Hospital, China
  18. [18] The Affiliated Hospital of Medical School of Ningbo University, China
  19. [19] Yueqing City People’s Hospital, China
  20. [20] Quzhou People’s Hospital, China
  21. [21] The First Provincial Wenzhou Hospital of Zhejiang, China
  22. [22] Taizhou Hospital of Zhejiang Province, China
  23. [23] Jiaxing First Hospital, China

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 21, Nº. 2 (February), 2019, págs. 167-177
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Purpose To assess the efficacy and safety of drug-eluting beads transarterial chemoembolization (DEB-TACE) in liver cancer patients with different times of previous conventional transarterial chemoembolization (cTACE) treatments.

    Methods 367 liver cancer patients about to receive DEB-TACE treatment were enrolled in this prospective cohort study. All patients were divided into no previous cTACE group (NPC group), 1–2 times previous cTACE group (PC group) and triple or above previous cTACE group (TPC group) according to the times of previous cTACE treatments.

    Results There was no difference in complete response (CR) (P = 0.671) and objective response rate (ORR) (P = 0.062) among three groups. Additionally, no difference in overall survival (OS) among groups (P = 0.899) was found. As to liver function, most liver function indexes were deteriorative at 1 week after DEB-TACE operation, but returned to baseline at 1–3 months after DEB-TACE operation in all three groups, while percentage of abnormal total bile acid (TBA) patients was higher in TPC group than NPC and PC groups at 1–3 month post-DEB-TACE (P = 0.018). As for safety profiles, the incidence of pain during DEB-TACE operation was lower in TPC group compared to NPC and PC groups (P = 0.005), while no difference of other adverse events was found during and 1 month post-DEB-TACE treatment among three groups.

    Conclusion DEB-TACE treatment was equally efficient and tolerated in liver cancer patients with different times of previous cTACE treatments.